MDM2 and melanoma: Although melanoma cells are highly resistant to MAPK inhibitors, a combination with MDM2 inhibitor, Nutlin-3A, resulted in elevated FBXW7 expression, p63 degradation, and apoptosis of melanoma cells effectively reversing MAPK inhibitor resistance [253].